Ellen Garber - Cambridge MA, US Linda Burkly - West Newton MA, US Jennifer Michaelson - Brighton MA, US Alexey Lugovskoy - Woburn MA, US Yen-Ming Hsu - Lexington MA, US Karl Hanf - Billerica MA, US
Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject.
- Cambridge MA, US Deborah Law - Cambridge MA, US Christopher Harvey - Boston MA, US Elizabeth G. Trehu - Cambridge MA, US Lauren Pepper MacKenzie - Cambridge MA, US Amit Deshpande - Cambridge MA, US Jennifer S. Michaelson - Brighton MA, US Igor Feldman - Jamaica Plain MA, US Sriram Sathyanarayanan - Lexington MA, US
- Cambridge MA, US Jennifer Michaelson - Cambridge MA, US Bochong Li - Boston MA, US Naveen Mehta - Cambridge MA, US Jonathan Belk - Lebanon NH, US Nathan Sharkey - Lebanon NH, US Bianka Prinz - Lebanon NH, US Bradley M. Lunde - Lebanon NH, US Nga Rewa Houston - Lebanon NH, US
International Classification:
C07K 16/28 A61P 31/04
Abstract:
Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.
- Cambridge MA, US Jennifer Michaelson - Cambridge MA, US Bochong Li - Boston MA, US Naveen Mehta - Cambridge MA, US Bianka Prinz - Lebanon NH, US Bradley M. Lunde - Lebanon NH, US Nga Rewa Houston - Lebanon NH, US
International Classification:
C07K 16/28 C07K 16/46
Abstract:
The invention relates to anti-serum albumin antibodies and multi-specific binding proteins comprising the same. The invention also relates to pharmaceutical compositions comprising the antibodies or multi-specific binding proteins, expression vectors and host cells for making the antibodies or multi-specific binding proteins, and methods of use of the antibodies or multi-specific binding proteins in treatment of diseases or disorders.
Name / Title
Company / Classification
Phones & Addresses
Jennifer Michaelson Scientist Ii Molecular Discovery
Cullinan Oncology
Chief Development Officer
Third Rock Ventures Jul 2017 - Dec 2017
Head of Biologics at Third Rock Ventures Newco
Jounce Therapeutics, Inc. Jul 1, 2016 - Jul 2017
Executive Program Leader and Senior Director of Pharmacology and Preclinical Development
Jounce Therapeutics, Inc. Jan 2013 - 2016
Director of Research, Tumor Immunology
Third Rock Ventures Sep 2012 - Dec 2012
Consultant
Education:
Harvard Medical School 1997 - 2002
Albert Einstein College of Medicine 1990 - 1996
Doctorates, Doctor of Philosophy
Princeton University 1986 - 1990
Bachelors, Bachelor of Arts
Skills:
Drug Discovery Immunology Biotechnology Cell Biology Oncology Assay Development Antibodies Monoclonal Antibodies Genetics Protein Chemistry Biochemistry Translational Research Cell Culture Cro Mouse Models Inflammation Genomics Business Development Protein Expression Leadership Clinical Development Team Leadership High Throughput Screening Biomarkers Life Sciences Antibody Therapeutics Project Leadership Pharmaceutical Industry Pharmacology Cro Management Biopharmaceuticals Drug Development Ind
Carol Hinckley, Jason Brunt, Roger Edwards, Richard Graham, Annette Levesque, Cynthia Zaitzevsky, Patricia Ellis, Sandra Chase, Barbara Doherty, Kerry Massey, Kathy Welch, John Savery